Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACON NASDAQ:BGLC NASDAQ:BRTX NASDAQ:MGRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONAclarion$7.17-1.9%$7.28$6.20▼$3,499.51$4.26M1.3413,554 shs14,533 shsBGLCBioNexus Gene Lab$5.57-1.6%$4.60$2.01▼$15.60$10.17M5.343.46 million shs84,157 shsBRTXBiorestorative Therapies$1.45+1.4%$1.63$1.21▼$2.55$10.73M76.783,726 shs25,554 shsMGRXMangoceuticals$1.86+1.1%$1.77$1.32▼$7.66$9.51M2.42136,838 shs65,296 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONAclarion-2.91%+2.58%-2.05%+0.99%-99.72%BGLCBioNexus Gene Lab-1.59%-13.91%-4.30%+108.61%+27.75%BRTXBiorestorative Therapies+1.40%+2.84%-10.49%-19.44%+9.85%MGRXMangoceuticals+1.09%+8.77%+27.40%+5.98%-97.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACONAclarion1.992 of 5 stars3.03.00.00.01.90.01.3BGLCBioNexus Gene Lab0.1463 of 5 stars0.03.00.00.01.10.00.0BRTXBiorestorative Therapies3.0502 of 5 stars3.55.00.00.00.03.30.6MGRXMangoceuticals0.991 of 5 stars0.03.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACONAclarion 2.00Hold$11,758.50163,895.82% UpsideBGLCBioNexus Gene Lab 0.00N/AN/AN/ABRTXBiorestorative Therapies 3.00Buy$18.001,141.38% UpsideMGRXMangoceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ACON, BGLC, BRTX, and MGRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025ACONAclarionAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACONAclarion$50K83.17N/AN/A$51.50 per share0.14BGLCBioNexus Gene Lab$9.51M1.05N/AN/A$4.63 per share1.20BRTXBiorestorative Therapies$400K27.19N/AN/A$1.23 per share1.18MGRXMangoceuticals$620K15.51N/AN/A$4.30 per share0.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACONAclarion-$6.99MN/A0.00N/AN/A-12,227.10%-126.89%-106.61%8/13/2025 (Estimated)BGLCBioNexus Gene Lab-$1.60MN/A0.00∞N/A-22.85%-24.18%-20.14%8/13/2025 (Estimated)BRTXBiorestorative Therapies-$8.98M-$1.47N/AN/AN/A-3,093.61%-129.47%-86.02%8/12/2025 (Estimated)MGRXMangoceuticals-$8.71M-$4.64N/A∞N/A-2,191.76%-72.81%-66.58%8/13/2025 (Estimated)Latest ACON, BGLC, BRTX, and MGRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ACONAclarion-$2.26N/AN/AN/AN/AN/A8/12/2025Q2 2025BRTXBiorestorative Therapies-$0.41N/AN/AN/A$0.34 millionN/A5/15/2025Q1 2025ACONAclarion-$1,447.20-$9.32+$1,437.88-$9.32$0.02 million$0.02 million5/15/2025Q1 2025BGLCBioNexus Gene LabN/A-$0.03N/A-$0.03N/AN/A5/15/2025Q1 2025MGRXMangoceuticalsN/A-$1.29N/A-$1.29N/A$0.11 million5/14/2025Q1 2025BRTXBiorestorative Therapies-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACONAclarionN/AN/AN/AN/AN/ABGLCBioNexus Gene LabN/AN/AN/AN/AN/ABRTXBiorestorative TherapiesN/AN/AN/AN/AN/AMGRXMangoceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACONAclarionN/A21.6821.68BGLCBioNexus Gene LabN/A4.193.44BRTXBiorestorative TherapiesN/A2.242.24MGRXMangoceuticalsN/A0.120.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACONAclarion7.52%BGLCBioNexus Gene Lab18.85%BRTXBiorestorative Therapies69.38%MGRXMangoceuticals56.72%Insider OwnershipCompanyInsider OwnershipACONAclarion0.77%BGLCBioNexus Gene Lab0.70%BRTXBiorestorative Therapies25.50%MGRXMangoceuticals16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACONAclarion7580,000578,000Not OptionableBGLCBioNexus Gene Lab301.80 million1.78 millionNot OptionableBRTXBiorestorative Therapies77.50 million5.59 millionNot OptionableMGRXMangoceuticals35.17 million4.34 millionNot OptionableACON, BGLC, BRTX, and MGRX HeadlinesRecent News About These CompaniesMangoceuticals Terminates Agreement with Navy WharfAugust 4, 2025 | tipranks.comMangoceuticals President Tony Isaac ResignsJuly 3, 2025 | tipranks.comMangoceuticals Strengthens Position with Equity TransactionsJune 10, 2025 | tipranks.comMangoceuticals files to sell 4.46M shares of common stock by selling shareholdersMay 30, 2025 | msn.comMangoceuticals, Inc.: Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian FluMay 29, 2025 | finanznachrichten.deMangoceuticals, Inc. Reports 100% Survival Rates in Field Studies of MGX-0024 for Poultry Respiratory DiseasesMay 29, 2025 | nasdaq.comMangoceuticals shares results from field studies on MGX-0024May 29, 2025 | finance.yahoo.comMangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian FluMay 27, 2025 | globenewswire.comMangoceuticals, Inc. Terminates Agreements with Key PartnersMay 23, 2025 | tipranks.comArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch MarketApril 28, 2025 | newsfilecorp.comNMangoceuticals Enters Wellness Pouch Market, Appoints Tim Corkum To Lead New UnitApril 27, 2025 | nasdaq.comMangoceuticals enters into agreement to acquire assets of Smokeless TechnologyApril 27, 2025 | markets.businessinsider.comCORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch SectorApril 26, 2025 | newsfilecorp.comNCORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch SectorApril 26, 2025 | newsfilecorp.comNArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch SectorApril 25, 2025 | newsfilecorp.comNMangoceuticals Acquires IP to Expand Product LineApril 25, 2025 | tipranks.comMangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch DivisionApril 25, 2025 | globenewswire.comMangoceuticals Is Reengineering the Self-Care Blueprint with Better Personal Health and Wellness SolutionsApril 24, 2025 | finance.yahoo.comCEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health LandscapeApril 22, 2025 | accessnewswire.comAMangoceuticals Issues Bonus Shares to LeadershipApril 11, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACON, BGLC, BRTX, and MGRX Company DescriptionsAclarion NASDAQ:ACON$7.17 -0.14 (-1.92%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$7.25 +0.08 (+1.12%) As of 08/8/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.BioNexus Gene Lab NASDAQ:BGLC$5.57 -0.09 (-1.59%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$5.50 -0.07 (-1.26%) As of 08/8/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.Biorestorative Therapies NASDAQ:BRTX$1.45 +0.02 (+1.40%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$1.44 0.00 (-0.34%) As of 08/8/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Mangoceuticals NASDAQ:MGRX$1.86 +0.02 (+1.09%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.80 -0.07 (-3.49%) As of 08/8/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
